Vertex Pharmaceuticals (VRTX) 10-K Summary — Year Ended Dec 31, 2023
The company reported annual financial results with revenue and operating income both showing growth. Cash from operations remained positive, supporting the company's financial position.
Key takeaway
Year ended Dec 31, 2023 · FY2025 10-K
The company reported annual financial results with revenue and operating income both showing growth. Cash from operations remained positive, supporting the company's financial position.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$9.9B
Revenue reported for the fiscal year.
Operating income
$3.8B
Income from operations reported for the year.
Net income
$3.6B
Net income reported for the year.
Operating cash flow
$3.5B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $7.6B | n/a |
| Dec 31, 2022 | $8.9B | +17.9% |
| Dec 31, 2023 | $9.9B | +10.5% |
Business overview
Vertex Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious diseases. The business overview section in the filing describes its operations and executive officers. The company's primary focus areas include cystic fibrosis and other serious disease treatments.
Financial performance
Revenue increased compared to the prior year, and operating income was reported at a level consistent with that growth. Net income and operating cash flow were also positive, reflecting continued profitability. The company's cash provided by operations remained strong.
Material risks
The risk factors section highlights uncertainties related to drug development, regulatory approvals, and market competition. Dependence on key products and potential adverse events in clinical trials are noted as material risks. The filing also points to risks from intellectual property disputes and changes in healthcare regulations.
Liquidity and capital
The company maintained a substantial working capital position, supported by income from operations. Cash flows from investing activities reflected net purchases of long-term marketable securities.
What to watch
Investors should monitor the company's progress with pipeline candidates and regulatory milestones for new indications. Investors should monitor the company's progress with pipeline candidates and regulatory milestones for new indications.